Saturday, June 6, 2020

Tag: Acorda Therapeutics

Acorda Therapeutics Announces Initiation of Phase 2 Trial of Treatment for Spinal Cord Injury

Published: September 25, 2013

acorda-therapeuticsAC105 improved motor function after spinal cord injury in preclinical studies

ARDSLEY, N.Y.–(BUSINESS WIRE)–Sep. 25, 2013– Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a trial of AC105, its proprietary magnesium formulation for the treatment of spinal cord injury (SCI). This Phase 2 trial will evaluate the safety and tolerability of the drug in people with traumatic SCI, and also incorporates several exploratory efficacy measures.

Working2Walk 2011, Anthony Caggiano (Acorda)

Published: October 24, 2011

The Challenges of Chondroitinase Development for Spinal Cord Injury

Do NOT follow this link or you will be banned from the site!